Core Viewpoint - The company, Boji Pharmaceutical, emphasizes its competitive edge in traditional Chinese medicine (TCM) research and development services, focusing on providing comprehensive TCM R&D services and enhancing its capabilities in the field [1] Group 1: Business Focus - The company primarily offers TCM R&D services through its wholly-owned subsidiary, Xinglin TCM, which provides clinical, preclinical, and registration services for TCM [1] - The company’s controlling subsidiary, Henan Kangli, specializes in post-marketing re-evaluation services for TCM [1] Group 2: Research and Development Achievements - In the past two years, the company has successfully developed TCM Class 1.2 CRA (raw materials and formulations) and Class 1.1 Qingzhi ointment, both of which have received the "Drug Clinical Trial Approval Notice" [1] - Several innovative TCM self-research projects are currently in the preclinical development stage [1] Group 3: Future Strategy - The company plans to continue prioritizing TCM R&D services while supplementing its self-research efforts and aims to attract more TCM R&D talent to enhance its competitiveness in the TCM sector [1]

Group 1 - The company, Boji Pharmaceutical, primarily focuses on the research and development of chemical drugs, with significant capabilities in liver disease, digestive disorders, tumors, and endocrine research services [1] - The company also provides services related to traditional Chinese medicine, biological drugs, and medical devices, but chemical drug development is the main area of expertise [1] - There is currently no authoritative statistical data available regarding the market share of the company's services [1]

Core Insights - The CXO (Contract Research Organization and Contract Development and Manufacturing Organization) sector in A-shares shows a mixed performance in the first half of the year, with 19 out of 35 companies reporting a year-on-year profit increase, indicating a positive trend in the industry [1] Group 1: Company Performance - WuXi AppTec leads the CXO companies with a net profit of 5.313 billion yuan, followed by Kelun Pharmaceutical with 1.686 billion yuan, and Tigermed with 1.388 billion yuan [2] - WuXi AppTec's revenue reached 18.871 billion yuan, a year-on-year increase of 6.28%, with a net profit growth of 14.61% [2] - Kelun Pharmaceutical reported a revenue of 4.622 billion yuan, a decline of 8.33%, and a net profit decrease of 3.09% [3] Group 2: Sector Trends - The demand for peptide drugs, traditional Chinese medicine, and ADC (Antibody-Drug Conjugates) is increasing, leading to significant order growth for some CXO companies [4] - WuXi AppTec's TIDES business, focusing on oligonucleotides and peptides, generated 1.33 billion yuan in revenue, a growth of 37.9%, with a backlog of orders increasing by 188% [4] - The CRO service provider Boji Pharmaceutical reported a 49% increase in new business contracts, with traditional Chinese medicine contracts growing by approximately 400% [4] Group 3: Market Expansion - Despite a cooling investment environment in the global pharmaceutical sector, several CXO companies are experiencing growth in overseas markets [5] - Kelun Pharmaceutical's revenue from U.S. clients reached 3.348 billion yuan, with a 44.77% increase when excluding large orders [5] - Tigermed's revenue was 3.711 billion yuan, a year-on-year increase of 3.25%, with a net profit growth of 16.47% [6]